Status:
UNKNOWN
Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity
Lead Sponsor:
Samsung Medical Center
Collaborating Sponsors:
Dong-A Pharmaceutical Co., Ltd.
Conditions:
Vascular Dementia
Subcortical Vascular Dementia
Eligibility:
All Genders
50-85 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether Zydena (Udenafil) has effect on cerebral blood flow and peripheral blood viscosity in normal and subcortical vascular cognitive impairment subjects.
Detailed Description
Udenafil is a newly developed selective phosphodiesterase type 5 inhibitor (PDE5i). Since PDE5i is known to relax smooth muscle cells, it is suggested that PDE5i may dilate cerebral vessels and lead t...
Eligibility Criteria
Inclusion
- for Normal control group
- Normal cognition by detailed neuropsychological tests
- Brain MRI scan with no or minimal white matter hyperintensities
- for Subcortical vascular mild cognitive impairment (svMCI)
- Clinical diagnosis of svMCI
- Brain MRI scan with severe white matter hyperintensities
Exclusion
- \- Contraindications to phosphodiesterase type 5 (Zydena, Udenafil)
Key Trial Info
Start Date :
November 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2012
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT01466543
Start Date
November 1 2011
End Date
November 1 2012
Last Update
November 8 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, South Korea, 135-710